The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy

2012 ◽  
Vol 2012 ◽  
pp. 163-164
Author(s):  
T.J. Fahey
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
131I Therapy

The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy

2010 ◽  
Vol 74 (1) ◽  
pp. 104-110 ◽  
Author(s):  
D. van Dijk ◽  
J. T. M. Plukker ◽  
A. N. A. van der Horst-Schrivers ◽  
L. Jansen ◽  
A. H. Brouwers ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
131I Therapy

scholarly journals Low iodine diet of four days is sufficient preparation for 131I therapy in differentiated thyroid cancer patients

2021 ◽  
Author(s):  
Bernadette L Dekker ◽  
Mirthe H Links ◽  
Anneke C Muller Kobold ◽  
Linda G Swart-Busscher ◽  
Marleen Kars ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Urinary Iodine ◽  
Iodine Intake ◽  
131I Therapy ◽  
Lower Percentage ◽  
Urinary Iodine Excretion ◽  
Food Diary ◽  
Iodine Excretion ◽  
The Difference

Abstract Context No consensus exists about the optimal duration of the low iodine diet (LID) in preparation of 131I therapy in differentiated thyroid cancer (DTC) patients. Objective This work aimed to investigate if a LID of four days is enough to achieve adequate iodine depletion in preparation for 131I therapy. In addition, the nutritional status of the LID was evaluated. Methods In this prospective study, 65 DTC patients treated in two University Medical Centers were included between 2018 and 2021. The patients collected 24-h urine on day four and seven of the LID and kept a food diary before and during the LID. The primary outcome was the difference between the 24-h urinary iodine excretion (UIE) on both days. Results The median 24-h UIE on day four and day seven of the LID were not significantly different (36.1[IQR 25.4 – 51.2]mcg and 36.5[IQR 23.9 – 47.7]mcg, respectively, P=0.43). On day four of the LID, 72.1% of the DTC patients were adequately prepared (24-h UIE<50 mcg), and 82.0% of the DTC patients on day seven(P=0.18). Compared to the self-reported regular diet, DTC patients showed a significantly(P<0.01) lower percentage of nutrient intake (calories, protein, calcium, iodine, and water) during the LID. Conclusions The 24-h UIE on day four of the LID did not differ from day seven, and therefore shortening the LID from seven to four days seems justified to prepare DTC patients for 131I therapy in areas with sufficient iodine intake and may be beneficial to maintain a sufficient nutritional intake during DTC treatment.

scholarly journals Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention

2021 ◽  
Vol 23 (5) ◽  
pp. 670-676
Author(s):  
M. V. Ostafiychuk ◽  
A. Ye. Kovalenko ◽  
Yu. M. Tarashchenko
Keyword(s):  
Thyroid Cancer ◽  
Surgical Treatment ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
131I Therapy ◽  
Control Group ◽  
Endocrine Gland ◽  
Age Group ◽  
Well Differentiated ◽  
The Impact

The aim of this article is to assess the initial status, characteristics of the tumor process and initial surgical treatment in patients with well-differentiated thyroid carcinomas who subsequently showed resistance to 131I therapy, comparing with the control group of patients who achieved a positive effect of 131I therapy. Materials and methods. In total, 156 cases of well-differentiated thyroid cancer were analyzed. The control group consisted of 189 patients who showed complete responses to treatment of metastases after 131I therapy and the confirmed relapse-free period. The patients were operated and followed up in the Department of Endocrine Gland Surgery of SI “V. P. Komisarenko Institute of Endocrinology and Metabolism of the National Academy of Medical Sciences of Ukraine” between 1990 and 2019. Results. Based on our study, in the group of radioiodine-resistant metastases, there was a 3.1:1.0 predominance of women over men; whereas in the control group, this ratio was 1.4:1.0. It was noted that resistance to radioactive iodine in patients under 20 years of age was 4 times significantly lower (10.26 %) comparing with the radiosensitive group (41.90 %). In the age group of 41–60 years, radioiodine resistance was 6.5 times higher than that in the comparison group (39.10 % and 6.35 %), and in the age group over 61 years – 11 times (11.54 % and 1.05 %). The impact analysis of radiation exposure on the radioiodine refractoriness occurrence revealed that among patients living in radiation-contaminated areas of Ukraine in 1986 following the Chornobyl accident, there were no significant differences in the development of resistance to radioactive iodine (resistance to 131I – 51.92 % (n = 81), treatment response 131I – 64.02 % (n = 121)). These differences may be due to the younger age of patients affected by radiation and better sensitivity to radioiodine compared to the main group patients. The maximum number of radioiodine-resistant observations was in the intermediate risk group (71.15 %; n = 111). Worth noting is the significant number of radioiodine-resistant metastases in the group where their absence was initially diagnosed (11.53 %; n = 18) and in the group where the proper assessment of lymph collectors was not performed (29.49 %; n = 46). Radioiodine resistance was significantly more common (33.97 %; n = 53) in observations where the prophylactic central dissection was not performed. Conclusions. The main risk factors in the development of radioiodine-resistant metastases were the age of patients older than 40 years, the limited primary surgery on regional lymphatic collectors of the neck, tumor aggressiveness. Careful pre- and intraoperative assessment of regional collectors of the lymph outflow, preventive central neck dissection and extensive therapeutic dissections can reduce the risk of residual and radioiodine-resistant metastases. Timely diagnosis of metastases can improve the results of primary surgical treatment for patients with differentiated thyroid carcinoma and reduce the incidence of radioiodine resistance.

Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)

2007 ◽  
Vol 46 (05) ◽  
pp. 213-219 ◽  
Author(s):  
J. Dressler ◽  
W. Eschner ◽  
F. Grünwald ◽  
M. Lassmann ◽  
B. Leisner ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
131I Therapy ◽  
131I Ablation ◽  
Procedure Guidelines ◽  
Lower Blood ◽  
Higher Sensitivity

SummaryThe procedure guideline for radioiodine therapy (RIT) of differentiated thyroid cancer (version 3) is the counterpart to the procedure guideline for 131I whole-body scintigraphy (version 3) and specify the interdisciplinary guideline for thyroid cancer of the Deutsche Krebsgesellschaft concerning the nuclear medicine part. Recommendation for ablative 131I therapy is given for all differentiated thyroid carcinoma (DTC) >1 cm. Regarding DTC ≤1 cm 131I ablation may be helpful in an individual constellation. Preparation for 131I ablation requires low iodine diet for two weeks and TSHstimulation by withdrawal of thyroid hormone medication or by use of recombinant human TSH (rhTSH). The advantages of rhTSH (no symptoms of hypothyroidism, lower blood activity) and the advantages of endogenous TSHstimulation (necessary for 131I-therapy in patients with metastases, higher sensitivity of 131I whole-body scan) are discussed. In most centers standard activities are used for 131I ablation. If pretherapeutic dosimetry is planned, the diagnostic administration of 131I should not exceed 1–10 MBq, alternative tracers are 123I or 124I. The recommendations for contraception and family planning are harmonized with the recommendation of ATA and ETA. Regarding the best possible protection of salivary glands the evidence is insufficient to recommend a specific setting. To minimize the risk of dental caries due to xerostomia patients should use preventive strategies for dental hygiene.

scholarly journals Clinical Assessment of Patients Undergoing Frequent 131I Therapy for the Metastasis from Differentiated Thyroid Cancer

1996 ◽  
Vol 72 (3) ◽  
pp. 457-466
Author(s):  
Takashi ISHIHARA ◽  
Katsuji IKEKUBO ◽  
Megumu HINO ◽  
Mariko KAJIKAWA ◽  
Naoki HATTORI ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Assessment ◽  
Differentiated Thyroid Cancer ◽  
131I Therapy
Sign in / Sign up

Export Citation Format

Share Document